References
- Ochs MA, Marini BL, Perissinotti AJ, et al. Oncology stewardship in acute myeloid leukemia. Ann Hematol. 2022;101(8):1627–1644.
- Zhao X, Liu HQ, Wang LN, et al. Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. Semin Cancer Biol. 2022;83:121–135.
- Pollyea DA, Bixby D, Perl A, et al. NCCN Guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27.
- Guo Y, Wang W, Sun H. A systematic review and meta-analysis on the risk factors of acute myeloid leukemia. Transl Cancer Res. 2022;11(4):796–804.
- Alahmari B, Alzahrani M, Al Shehry N, et al. Management approach to acute myeloid leukemia leveraging the available resources in view of the latest evidence: consensus of the saudi society of blood and marrow transplantation. J Clin Oncol Glob Oncol. 2021;7:1220–1232.
- Sophie S, Yves B, Frederic B. Current status and perspectives of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia. Stem Cells Transl Med. 2022;11(5):461–477.
- Kreidieh F, Abou Dalle I, Moukalled N, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022;116(3):330–340.
- Ishii H, Yano S. New therapeutic strategies for adult acute myeloid leukemia. Cancers (Basel. 2022;14(11):2806.
- Kunz K, Piller T, Muller S. SUMO-specific proteases and isopeptidases of the SENP family at a glance. J Cell Sci. 2018;131(6):jcs211904.
- Niu Q, Hou W, Yan Y, et al. Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1. Biochim Biophys Acta Mol Basis Dis. 2022;1868(12):166492.
- Wang FF, Liu MZ, Sui Y, et al. Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia. Oncol Lett. 2016;12(5):3755–3762.
- Zhang Y, Ma Y, Wu G, et al. SENP1 promotes MCL pathogenesis through regulating JAK-STAT5 pathway and SOCS2 expression. Cell Death Discov. 2021;7(1):192.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
- Liu K, Zhang J, Wang H. Small ubiquitin-like modifier/sentrin-specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non-small cell lung cancer. J Clin Lab Anal. 2018;32(9):e22611.
- Wang Z, Jin J, Zhang J, et al. Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells. Oncol Rep. 2016;36(4):2071–2078.
- Chen MC, Nhan DC, Hsu CH, et al. SENP1 participates in irinotecan resistance in human colon cancer cells. J Cell Biochem. 2021;122(10):1277–1294.
- Ma Y, Li T, Feng R, et al. Synergistic role of JAK/STAT5 and PI3K/AKT signaling pathways in regulating eIF4B in acute leukemia. Sheng Wu Gong Cheng Xue Bao. 2020;36(11):2413–2423.
- Xia W, Tian H, Cai X, et al. Inhibition of SUMO-specific protease 1 induces apoptosis of astroglioma cells by regulating NF-kappaB/Akt pathways. Gene. 2016;595(2):175–179.
- Di Francesco B, Verzella D, Capece D, et al. NF-kappaB: a druggable target in acute myeloid leukemia. Cancers. 2022;14(14):3557.
- Huang X, Zuo Y, Wang X, et al. SUMO-Specific protease 1 is critical for myeloid-derived suppressor cell development and function. Cancer Res. 2019;79(15):3891–3902.
- Zhao S, Pan H, Guo Q, et al. Platelet to white blood cell ratio was an independent prognostic predictor in acute myeloid leukemia. Hematology. 2022;27(1):426–430.
- Alsulami HA, Alnashri MM, Bawazir AF, et al. Prognostics and clinical outcomes in patients diagnosed with acute myeloid leukemia (AML) in a teaching hospital. Cureus. 2021;13(10):e18915.
- Baik H, Boulanger M, Hosseini M, et al. Targeting the SUMO pathway primes all-trans retinoic acid-induced differentiation of nonpromyelocytic acute myeloid leukemias. Cancer Res. 2018;78(10):2601–2613.
- Gatel P, Brockly F, Reynes C, et al. Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies. Life Sci Alliance. 2020;:3(6):e201900577..